Merck on Vioxx vs. Celebrex
Vioxx (rofecoxib) continues to gain share in COX-2 inhibitor market, Merck says. Merck claims to hold a greater than 50% share of the Ob/Gyn, neurology, urology and dental specialty markets, with a 47% share of new prescriptions in the general practitioner market. New prescriptions for Vioxx in June were 900,000, Merck said. The product generated $375 mil. in U.S. sales during the quarter
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth